Back to top
more

Senseonics (SENS)

(Delayed Data from AMEX)

$0.46 USD

0.46
8,641,681

0.00 (1.03%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $0.45 -0.01 (-2.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (81 out of 245)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why Senseonics (SENS) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Senseonics (SENS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Senseonics (SENS) delivered earnings and revenue surprises of 0.00% and +4.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Outset Medical (OM): Can Its 15.0% Jump Turn into More Strength?

by Zacks Equity Research

Outset Medical (OM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

DXCM's Access Gains and Operational Strength Offset Margin Pressures

by Zacks Equity Research

DXCM rides on record patient growth and T2D access gains, but margin pressure and FDA scrutiny cloud the outlook.

Zacks Equity Research

Here's Why Senseonics (SENS) is Poised for a Turnaround After Losing 5.7% in 4 Weeks

by Zacks Equity Research

The heavy selling pressure might have exhausted for Senseonics (SENS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Senseonics (SENS) delivered earnings and revenue surprises of 0% and 16.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Senseonics (SENS) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Senseonics (SENS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Senseonics Holdings (SENS) Reports Q4 Loss

by Zacks Equity Research

Senseonics (SENS) delivered earnings and revenue surprises of 33.33% and 0%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Butterfly Network, Inc. (BFLY) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Butterfly Network (BFLY) delivered earnings and revenue surprises of 20% and 0.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Senseonics Holdings (SENS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Senseonics (SENS) delivered earnings and revenue surprises of -33.33% and 5.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Senseonics Stock Down Despite New FDA Approval for Eversense 365

by Zacks Equity Research

SENS' latest regulatory clearance is likely to simplify diabetes management with the help of a long-lasting CGM system.

Zacks Equity Research

Sonendo, Inc. (SONX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sonendo (SONX) delivered earnings and revenue surprises of 33.33% and 9.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

SOPHiA GENETICS (SOPH) delivered earnings and revenue surprises of 17.86% and 10.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Senseonics' (SENS) Deal With Mercy to Drive Eversense CGM Sales

by Zacks Equity Research

Senseonics Holdings (SENS) collaborates with Mercy to bring its Eversense CGM to a healthcare system that is likely to drive its adoption.

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 28.57% and 9.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Senseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Senseonics (SENS) delivered earnings and revenue surprises of 25% and 4.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Phreesia (PHR) Surges 10.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Senseonics Holdings (SENS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Senseonics (SENS) delivered earnings and revenue surprises of 0% and 10.01%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

10x Genomics (TXG) delivered earnings and revenue surprises of -35.90% and 5.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Senseonics (SENS) delivered earnings and revenue surprises of 0% and 35.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Health Catalyst (HCAT) delivered earnings and revenue surprises of 50% and 1.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 7.32% and 11.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Computer Programs and Systems (CPSI) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of 3.39% and 2.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE